WO 2003/043537 A1 is an international (PCT) patent application with the title Improvements in curing AIDS with tetrasilver tetroxide molecular crystal devices. It was filed on 19 November 2001 under application number PCT/US2001/043227 and published on 30 May 2003. The Google Patents record names the inventor as Marvin W. Antelman, a middle initial that differs from the Marvin S. Antelman used elsewhere in this dossier, and gives Marantech Holding LLC as assignee. The application builds on Antelman's earlier US Patent 5,676,977 (priority 22 September 1994, issued 14 October 1997, assigned to Antelman Technologies Ltd.), the AIDS-cure patent discussed across the Tetrasilver Tetroxide (Ag₄O₄) pages.
The document matters because it ties the AIDS assertion to individual patient outcomes: seven South African patients, most of them described as cured or recovered within 30 days. It is also where the inventor acknowledges that most patients given an earlier protocol developed an enlarged liver.
What the application claims to improve
The application presents itself as a refinement of the treatment set out in the 1997 patent. Tetrasil is the trademark it uses for the tetroxide product, owned by Marantech, with a US registration said to be pending. It names two objects. The first is to reduce side effects in AIDS patients given Tetrasil, especially hepatomegaly (an enlarged liver). The second is to quantify intravenous treatment for non-terminal patients.
The application's description proposes revised intravenous protocols for non-terminal and terminal patients, with the change for terminal patients presented as a way of reducing side effects. The document is not internally consistent on this point: the protocol its worked example reports for non-terminal patients does not match the one its summary assigns to them, and it does not explain the discrepancy.
The admission about the earlier protocol
The application refers to a Table (I) in US 5,676,977 summarising terminal patients from two groups, Candidiasis and Wasting Syndrome, and states that eight of the ten patients in it developed hepatomegaly. The inventor judges the enlargement harmless on the grounds that no liver-enzyme abnormality was seen. It does not say how the enlargement was detected, how large it was, or whether it resolved.
So the patentee's own record concedes reported liver enlargement in eight of the ten patients from the earlier patent's table. Avoiding that effect is the stated reason for the new application.
The mechanism as restated
The application repeats the molecular-device picture from the earlier patents (see Molecular Crystal Device (Electron Jumping Compound) and Electron Jumping Compound / Molecular Battery Claim). A single crystal of Ag₄O₄ is described as a diamagnetic semiconductor holding two monovalent and two trivalent silver ions. Electrons said to be released by the crystal are claimed to destroy the AIDS virus, other pathogens and a category the document labels immune suppressing moieties, abbreviated ISM. It adds a second, simultaneous route. The internal redox step oxidises the monovalent silver and reduces the trivalent silver, producing divalent silver, which the application says binds and chelates at active sites on the virus, pathogens and ISM. The document gives no measurement of either process in blood or in patients.
The reported cases
The application describes seven patients treated at a South African clinic, each given a single injection. Its second example covers three patients described as non-terminal, treated in the summer of 2001; its third covers four terminal patients with Wasting Syndrome, treated in the same way by the same clinic, with no date given.
What is reported. The outcomes are almost entirely clinical impressions. Of the three non-terminal patients (a 41-year-old man with Wasting Syndrome, and a 38-year-old woman and a 34-year-old man with the P. carinii pneumonia form of AIDS), the application says the man was "completely cured" within 30 days and the other two were cured of both AIDS and pneumonia, with no relapse seen at 60 days. Among the four terminal patients (two women aged 29 and 30, two men aged 30 and 33), one man who also had pulmonary TB and oesophageal Candida is reported to have gained 22 pounds over two weeks and to have reached full recovery by 30 days. The other man is said to have recovered within 30 days, with no relapse at 60 days and a lifted mood. The 29-year-old woman is said to have been cured within 30 days. The evidence offered for these outcomes is weight gain, alertness, mood and a return to work or job-seeking.
What is left unreported. No outcome is stated for the 30-year-old woman; the text says only that she began in worse shape than the 29-year-old. No laboratory markers such as viral load or CD4 counts appear in any case. The application notes that some patients had a 30-day examination but no 60-day one, because their reports came in before 60 days had passed, so follow-up for several patients ends at a month.
What the document does and does not establish
These are case narratives written by the patentee for a patent filing. They are not a clinical study. There is no control group, no randomisation and no blinding. The document does not say who examined the patients or how, or how the diagnosis of AIDS or a cure was defined. Follow-up is 60 days at most, and for some patients 30. The application does not report whether any of the seven developed hepatomegaly, even though avoiding it is its main stated object. Filing or publishing a patent application is not evidence of effectiveness.
What happened to the application
The record lists the application as Ceased, with an anticipated expiration of 19 May 2004. The legal events show no entry into the European phase (recorded 5 January 2005) and none in Japan (recorded 17 January 2006). The Australian counterpart, AU 2001297566 A1, was published on 10 June 2003 and is listed as abandoned. The only patent the record cites is US 5,676,977, Antelman's own.
How it fits the dossier
This filing sits in the AIDS group of the patent list on Marvin Antelman, where it appears as WO03043537. Its contribution to the dossier is case-level detail behind the single-injection AIDS claim, together with the inventor's own figure of eight hepatomegaly cases in ten. For how this compares with the dossier's other claims and their evidential limits, see Tetrasilver Tetroxide: The Electron-Jumping Claim, the Patent Set and the Bounded Evidence. For the Tetrasil name in its later commercial setting, see TSTO Product Line (Tetrasilver Tetroxide Formulations).
Source notes & attribution
- https://patents.google.com/patent/WO2003043537A1/en